- Home
- CNTA
as 06-20-2025 4:00pm EST
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
| Founded: | 2020 | Country: | United Kingdom |
| Employees: | 86 | City: | ALTRINCHAM, CHESHIRE |
| Market Cap: | 1.6B | IPO Year: | 2021 |
| Target Price: | $27.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.46 - $19.09 | Next Earning Date: | 08-12-2025 |
| Revenue: | $15,000,000 | Revenue Growth: | 118.88% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Centessa Pharmaceuticals plc (CNTA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Weinhoff Gregory M | CNTA | Chief Business Officer | May 27 '25 | Sell | $12.82 | 10,000 | $128,225.00 | 122,279 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | May 20 '25 | Sell | $12.71 | 55,000 | $699,110.50 | 221,017 | |
| GOYAL ARJUN | CNTA | Director | May 15 '25 | Buy | $12.49 | 462,585 | $5,865,242.37 | 462,585 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | May 1 '25 | Sell | $14.00 | 311 | $4,354.00 | 105,386 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | Apr 25 '25 | Sell | $14.00 | 5,689 | $79,658.01 | 105,386 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Apr 25 '25 | Sell | $13.61 | 11,742 | $159,856.76 | 122,279 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Apr 21 '25 | Sell | $12.36 | 55,000 | $681,576.18 | 221,017 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Mar 25 '25 | Sell | $16.34 | 10,000 | $163,386.00 | 122,279 |
Latest Centessa Pharmaceuticals plc News
CNTA Breaking Stock News: Dive into CNTA Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
European Equities Traded in the US as American Depositary Receipts Edge Higher Wednesday
TipRanks
4 days ago
Centessa announces clearance of IND for ORX142
Zacks
5 days ago
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?
MT Newswires
5 days ago
Centessa Gets US FDA's Clearance to Start Phase 1 Trial of ORX142 for Neurological, Neurodegenerative Disorders
GlobeNewswire
5 days ago
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
Zacks
17 days ago
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet
MT Newswires
24 days ago
Needham Initiates Centessa Pharmaceuticals ADR at Buy With $35 Price Target
MT Newswires
a month ago
Centessa Pharmaceuticals Insider Sold Shares Worth $699,111, According to a Recent SEC Filing
Compare CNTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTA Centessa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.